Peringkat dalam Saham
#23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Harga Saham
$1.81
Terakhir disinkronkan: 2026-08-21
Kapitalisasi Pasar
$77.00M
Perubahan (1 tahun)
-23.63%
Perdagangan Annovis Bio, Inc. (ANVS)
Harga ANVS dengan kapitalisasi pasar B
Kapitalisasi pasar dari Annovis Bio, Inc.(ANVS)
Kapitalisasi Pasar: $77.00M
Per August 2026, Annovis Bio, Inc. memiliki kapitalisasi pasar sebesar $77.00M. Ini menjadikan Annovis Bio, Inc. sebagai perusahaan 23205th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Annovis Bio, Inc. dari 2020 hingga 2026
ANVS dibandingkan dengan 5 teratas stocks paling populer
| Harga ANVS |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.211T
|
+6,767,871.37%
|
|
|
|
|
$4.547T
|
+5,904,729.87%
|
|
|
|
|
$4.162T
|
+5,405,680.85%
|
|
|
|
|
$3.593T
|
+4,665,834.28%
|
|
|
|
|
$2.793T
|
+3,626,962.00%
|
